Q4 2023 Holdings
Filed 2024-03-07 | 9 holdings | $339.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $132.2M | 11,831,461 | 38.9% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $81.5M | 6,131,079 | 24.0% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $80.1M | 8,677,951 | 23.6% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $41.0M | 4,866,499 | 12.1% |
| Engene Holdings Inc(ENGNW) | W EXP 10/31/2028 | 29286M113 | $2.4M | 3,878,148 | 0.7% |
| Achilles Therapeutics PLC(698) | SPONSORED ADS | 00449L102 | $2.1M | 2,390,050 | 0.6% |